Cosmo Pharmaceuticals Announces First Patient Randomized In Its Proof Of Concept Phase II Clinical Trial Of Rifamycin SV in IBS-D
(WorldNews Netherlands)

This Randomized, Placebo Controlled Trial Will Investigate The Efficacy And Safety Of Two Doses Of Rifamycin-SV Compared To Placebo Dublin - December 12, 2017 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that the first patient has been randomized in its phase II clinical trial of Rifamycin SV for diarrhoea predominant Irritable Bowel Syndrome (IBS-D). This proof of concept study will investigate if Rifamycin SV tablets can relieve the abdominal pain and diarrhoea experienced by these patients compared to placebo treatment. `We are excited to achieve this important milestone, that will contribute to expand our Rifamycin SV franchise to new indications` said Alessandro Della Chà,...